SEC Form 8-K Summary
Registrant: Bull Horn Holdings Corp. Filing date: April 19, 2022, reporting an April 18, 2022 event. The provided filing is for Bull Horn Holdings Corp., not Z Squared Inc. Bull Horn is a British Virgin Islands special purpose acquisition company with securities listed on Nasdaq.
Business Context and Transaction
On April 18, 2022, Bull Horn entered into a merger agreement with BH Merger Sub Inc. and Coeptis Therapeutics, Inc. The transaction contemplates Bull Horn’s re-domestication from the British Virgin Islands to Delaware, followed by the merger of Merger Sub with Coeptis. Coeptis would survive as a wholly owned subsidiary of Bull Horn.
At closing, Bull Horn expects to change its name to Coeptis Therapeutics Holdings, Inc. The transaction requires approval by Bull Horn shareholders and Coeptis stockholders, as well as effectiveness of an SEC Form S-4 registration statement/proxy statement.
Financial Metrics and Consideration
- Aggregate merger consideration is based on $175.0 million, adjusted for Coeptis indebtedness net of cash and unpaid transaction expenses and bonuses at closing.
- Consideration to Coeptis stockholders will be paid solely in new Bull Horn common shares, valued at the redemption price applicable to Bull Horn public shareholders in connection with the transaction.
- Specified Coeptis warrants will be assumed and converted into warrants for Bull Horn common stock.
- Coeptis convertible debt and certain other obligations totaled approximately $3.9 million as of the merger agreement date. This permitted debt will not reduce the merger consideration.
- The agreement contains no minimum cash condition.
- Bull Horn must satisfy a $5,000,001 minimum net tangible asset condition at closing.
- The filing does not provide current or comparable-period revenue, profit, cash flow, operating margin, cash balance, or liquidity figures.
Material Changes and Governance
- The principal material change is Bull Horn’s entry into the definitive merger agreement with Coeptis.
- Following closing, the board is expected to have seven directors, with a majority independent under Nasdaq requirements. Coeptis would designate five directors and Bull Horn would designate two.
- The post-closing chief executive officer and chief financial officer are expected to be the same individuals serving in those roles at Coeptis immediately before closing.
- Shareholder approval will also be sought for a new equity incentive plan covering awards equal to 10% of post-closing issued and outstanding shares and amendments to Bull Horn’s organizational documents.
Outlook, Conditions, and Risks
- The parties intend to file the Form S-4 and conduct shareholder meetings, but the filing does not provide a definitive closing date.
- The outside date for completing the transaction is November 3, 2022, subject to the agreement’s termination provisions.
- Closing conditions include shareholder approvals, regulatory and third-party consents, an effective registration statement, Nasdaq listing approval, satisfaction of the net tangible asset test, and the absence of a continuing material adverse effect.
- The transaction may be terminated by mutual consent, failure to close by the outside date, a final prohibitory governmental order, uncured material breach, certain material adverse effects, or failure to obtain required shareholder approval. No termination fee is provided.
- Risks include failure to complete the transaction, significant redemptions by Bull Horn public shareholders, insufficient post-closing funds, loss of Nasdaq listing, disruption to Coeptis operations, failure to realize anticipated benefits, competition, difficulty hiring or retaining personnel, and failure of Coeptis products to complete clinical trials or obtain regulatory approval.
- Coeptis has waived any claim to Bull Horn’s trust account.
- Certain Coeptis stockholders agreed to vote in favor of the transaction and accepted restrictions on transfers, subject to specified permitted transfers.
Investor Verification Checklist
- Confirm that the filing relates to Bull Horn Holdings Corp. rather than Z Squared Inc.
- Review the subsequent Form S-4, proxy statement/prospectus, and definitive shareholder voting results.
- Verify the amount of Bull Horn shareholder redemptions, trust-account proceeds, and cash available at closing.
- Reconcile the final merger consideration for changes in Coeptis debt, cash, transaction expenses, and bonuses.
- Confirm whether all closing conditions were satisfied and whether the transaction closed by November 3, 2022.
- Review Coeptis’s financial statements, product pipeline, clinical-trial status, regulatory risks, and outstanding convertible debt.